Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eurand, SourceCF Inc. deal

EURX acquired SourceCF for $6.6 million in cash and up to $3

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE